TTY Biopharm Company Limited (TPEX:4105)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
85.30
+1.10 (1.31%)
Mar 2, 2026, 1:30 PM CST
7.57%
Market Cap 20.94B
Revenue (ttm) 6.50B
Net Income (ttm) 1.79B
Shares Out 248.65M
EPS (ttm) 7.19
PE Ratio 11.71
Forward PE 14.20
Dividend 4.20 (4.99%)
Ex-Dividend Date Mar 27, 2025
Volume 985,077
Average Volume 744,424
Open 84.20
Previous Close 84.20
Day's Range 84.00 - 85.60
52-Week Range 66.20 - 87.00
Beta 0.03
RSI 57.93
Earnings Date Mar 13, 2026

About TTY Biopharm Company

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through the Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epi... [Read more]

Sector Healthcare
Founded 1960
Employees 342
Stock Exchange Taipei Exchange
Ticker Symbol 4105
Full Company Profile

Financial Performance

In 2024, TTY Biopharm Company's revenue was 5.89 billion, an increase of 7.05% compared to the previous year's 5.51 billion. Earnings were 1.45 billion, an increase of 28.45%.

Financial Statements

News

There is no news available yet.